BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36361964)

  • 1. Th2 Cytokines (Interleukin-5 and -9) Polymorphism Affects the Response to Anti-TNF Treatment in Polish Patients with Ankylosing Spondylitis.
    Biały S; Iwaszko M; Świerkot J; Bugaj B; Kolossa K; Jeka S; Bogunia-Kubik K
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361964
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Iwaszko M; Wielińska J; Świerkot J; Kolossa K; Sokolik R; Bugaj B; Chaszczewska-Markowska M; Jeka S; Bogunia-Kubik K
    Front Immunol; 2021; 12():631603. PubMed ID: 34177886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms within Genes Coding for IL-17A and F and Their Receptor as Clinical Hallmarks in Ankylosing Spondylitis.
    Wielińska J; Świerkot J; Kolossa K; Bugaj B; Chaszczewska-Markowska M; Jeka S; Bogunia-Kubik K
    Mediators Inflamm; 2021; 2021():3125922. PubMed ID: 34744511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of ERAP1 gene single nucleotide polymorphisms in immunomodulation of pro-inflammatory and anti-inflammatory cytokines profile in ankylosing spondylitis.
    Babaie F; Mohammadi H; Hemmatzadeh M; Ebrazeh M; Torkamandi S; Yousefi M; Hajaliloo M; Rezaiemanesh A; Salimi S; Salimi R; Safarzadeh E; Baradaran B; Babaloo Z
    Immunol Lett; 2020 Jan; 217():31-38. PubMed ID: 31711818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of
    Braga M; Lara-Armi FF; Neves JSF; Rocha-Loures MA; Terron-Monich MS; Bahls-Pinto LD; de Lima Neto QA; Zacarias JMV; Sell AM; Visentainer JEL
    Front Immunol; 2021; 12():653611. PubMed ID: 34290697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aquaporin-1 expression as an indicator in evaluating the efficacy of meloxicam in the treatment of ankylosing spondylitis: A comparative study.
    Pan JE; Xiong FL; Chen G; Zhang ZW; Xu YJ
    Biomed Pharmacother; 2017 Nov; 95():1549-1555. PubMed ID: 28950654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of TNFRSF1A and TNFRSF1B polymorphisms in susceptibility, severity, and therapeutic efficacy of etanercept in human leukocyte antigen-B27-positive Chinese Han patients with ankylosing spondylitis.
    Xing-Rong W; Sheng-Qian X; Wen L; Shan Q; Fa-Ming P; Jian-Hua X
    Medicine (Baltimore); 2018 Aug; 97(31):e11677. PubMed ID: 30075559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association analysis of polymorphisms in IL-3, IL-4, IL-5, IL-9, and IL-13 with Graves' disease.
    Zhu W; Liu N; Zhao Y; Jia H; Cui B; Ning G
    J Endocrinol Invest; 2010 Nov; 33(10):751-5. PubMed ID: 20332709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variations in the IL-12B gene in association with IL-23 and IL-12p40 serum levels in ankylosing spondylitis.
    Ivanova M; Manolova I; Miteva L; Gancheva R; Stoilov R; Stanilova S
    Rheumatol Int; 2019 Jan; 39(1):111-119. PubMed ID: 30443744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically determined high activities of the TNF-alpha, IL23/IL17, and NFkB pathways were associated with increased risk of ankylosing spondylitis.
    Sode J; Bank S; Vogel U; Andersen PS; Sørensen SB; Bojesen AB; Andersen MR; Brandslund I; Dessau RB; Hoffmann HJ; Glintborg B; Hetland ML; Locht H; Heegaard NH; Andersen V
    BMC Med Genet; 2018 Sep; 19(1):165. PubMed ID: 30208882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synergistic role of TNFA - 308G/A and IL10 - 1082A/G polymorphisms in ankylosing spondylitis.
    Ivanova M; Manolova I; Stoilov R; Stanilova S
    Rheumatol Int; 2021 Dec; 41(12):2215-2224. PubMed ID: 34480606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nonsteroidal anti-inflammatory drugs on serum proinflammatory cytokines in the treatment of ankylosing spondylitis.
    Yan Y; Guo TM; Zhu C
    Biochem Cell Biol; 2018 Aug; 96(4):450-456. PubMed ID: 29324184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiologic parameters of ankylosing spondylitis patients treated with anti-TNF-α versus nonsteroidal anti-inflammatory drugs and sulfasalazine.
    Son SM; Choi SH; Shin JK; Goh TS; Lee JS
    Eur Spine J; 2019 Apr; 28(4):649-657. PubMed ID: 30742244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility to ERAP1 gene single nucleotide polymorphism modulates the inflammatory cytokine setting in ankylosing spondylitis.
    Hemmatzadeh M; Babaie F; Ezzatifar F; Mohammadi FS; Ebrazeh M; Golabi Aghdam S; Hajaliloo M; Azizi G; Gowhari Shabgah A; Shekari N; Sehati N; Hosseinzadeh R; Mohammadi H; Babaloo Z
    Int J Rheum Dis; 2019 Apr; 22(4):715-724. PubMed ID: 30740926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-α promoter -308/238 polymorphism association with less severe disease in ankylosing spondylitis is unrelated to serum TNF-α and does not predict TNF inhibitor response.
    Nossent JC; Sagen-Johnsen S; Bakland G
    J Rheumatol; 2014 Aug; 41(8):1675-82. PubMed ID: 25028373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline Interleukin-6 and Erythrocyte Sedimentation Rate Can Predict Clinical Response of TNF Inhibitor Treatment in Patients with Ankylosing Spondylitis.
    Dong Y; Guo J; Bi L
    Ann Clin Lab Sci; 2019 Sep; 49(5):611-618. PubMed ID: 31611204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of HLA-B27, tumor necrosis factor-α promoter gene polymorphisms, and T cell cytokine production in ankylosing spondylitis -- a comprehensive genotype-phenotype analysis from an observational cohort.
    Poddubnyy DA; Märker-Hermann E; Kaluza-Schilling W; Zeidler H; Braun J; Listing J; Sieper J; Rudwaleit M
    J Rheumatol; 2011 Nov; 38(11):2436-41. PubMed ID: 21885496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients.
    Milanez FM; Saad CG; Viana VT; Moraes JC; Périco GV; Sampaio-Barros PD; Goncalves CR; Bonfá E
    Arthritis Res Ther; 2016 Feb; 18():52. PubMed ID: 26912133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis.
    Tong Q; Zhao L; Qian XD; Zhang LL; Xu X; Dai SM; Cai Q; Zhao DB
    Pharmacogenomics; 2013 Nov; 14(14):1691-700. PubMed ID: 24192118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PBMC CDC42 reveals the disease activity and treatment efficacy of TNF inhibitor in patients with ankylosing spondylitis.
    Zhang Q; Jin D; Mou X; Ye H
    J Clin Lab Anal; 2022 Mar; 36(3):e24267. PubMed ID: 35104386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.